JC Discovery

keyboard_backspaceBack to Home

Contact

location_on

163 Av. de Luminy
13009 Marseille
France

public

https://www.jc-discovery.com/

Quentin Lecocq
BD
mail

quentin.lecocq@jc-discovery.com

call

+33675177351

About us

JC Discovery is a CRO offering preclinical services in the field of inflammation, auto-immune diseases and immuno-oncology. With a team of multidisciplinary experts and strategic partnerships in place, we are uniquely positioned to drive innovation through all pre-clinical stages of your drug development journey.

Business offer

JC Discovery® offers the combination of predictive preclinical models and innovative translational services that originate from its two founding entities, the Center of Immunophenomics (CIPHE; INSERM, CNRS, AMU) and Janvier Labs, both located in France.  

The unique JC Discovery® knowledge environment offers a comprehensive range of services permitting to develop in vitro and in vivo gene-edited preclinical models and to characterize the mouse, rat, and human immune systems using high-content immune-profiling.

At JC Discovery®, we support pharma and biotech strategic drug development in the field of immuno-oncology, inflammation, and auto-immune diseases. 

With academic connections, know-how, state-of-the-art technology platforms, and integrated data analysis, JC Discovery® also developed an innovative Fast-TrackTM pipeline based on CAR/TCR-T cells, primary human T-cells and omics, aiming at identifying, validating and prioritizing drug targets and at elucidating the mechanisms of action of new innovative immuno-therapeutics.

Activities

    Categories

    • Service

    Therapeutic applications

    • Genetic Diseases
    • Oncology
    • Hematology
    • Infectiology
    • Immunology
    • Inflammation

    Expertises

    Directory of Antibodies, Recombinant proteins and others
    • Target selection & validation
    • Gene / protein discovery
    • bioinformatics design
    • Expression and pathway analysis of target
    • quantification of target
    • Assay development in in-vitro & in-vivo models
    • Research exploratory companion biomarkers
    • Immunotherapy lead generation
    • Functional effects
    • ADCC, ADCP & CDC
    • Antigen density target
    • Internalization
    • Cell activation
    • Avidity testing
    • Cell-based activation (APCs, AAPCs)
    • Bead-base activation
    • Antibody-based activation
    • Ex-vivo activation (cell transfer)
    • In-vivo activation (in human transgenic mouse models)
    • Gene modification / Transduction
    • Retroviral & lentiviral vectors
    • Transposon/transposase
    • mRNA electroporation
    • CRISPR/Cas9
    • Immunotherapy lead optimization
    • Proof of concept
    • Pharmacology potency
    • Exploratory toxicology
    • in-vitro & ex-vivo models
    • in-vivo models
    • Preclinical biomarkers
    • Mechanism/Function
    • Mechanism of action
    • Safety
    • PK/PD features
    • Indication Identification
    • Exploratory toxicology
    • Drug-Target interaction
    • Level of response duration
    • Specificity
    • Surrogate markers
    • Research exploratory Companion biomarkers
    • Bioinformatics design
    • Bioinformatics prediction & analysis
    • Animal biomarkers
    • Human biomarkers
    • Predictive biomarkers
    • Treatment efficacy
    • Population stratification
    • Risk/benefit profile
    • Disease progression / follow-up
    Cell Therapy Directory
    • Cell origin
    • Single donor
    • Pool of donors
    • Cell Banking
    • IPs
    • MSC
    • CD34 + HSC cells
    • Tissue acquisition
    • Target cell isolation
    • Differentiated Cell
    • Production Cell
    • Safety donor-derived therapies
    • Cell modification
    • Direct reprogramming
    • Cell Activation
    • Ex Vivo & In Vivo Strategy
    • Ex Vivo & In Vivo Strategy
    Gene and CAR-T cell therapy Directory
    • Target Identification
    • Gene / protein discovery
    • bioinformatics design
    • Expression and pathway analysis of target
    • quantification of target
    • Assay development in in-vitro & in-vivo models
    • Research exploratory companion biomarkers
    • Gene Cloning
    • Gene augmentation
    • Gene inhibition
    • Killing Gene
    • KI / KO
    • (Gene) engineering
    • CRISPR activation
    • CRISPR interference
    • TRAC gene editing
    • Gene Delivery System
    • Lentivirus
    • Other Retrovirus
    • Adeno-Associated Virus (AAV)
    • Adenovirus (ADV)
    • Electroporation
    • Biomarker Identification
    • Research exploratory Companion biomarkers
    • Bioinformatics design
    • Bioinformatics prediction & analysis
    • Binder Generation
    • Mouse immunization
    • In silico
    • Hybridoma
    • CAR Construction
    • Intracellular Domain
    • T-cell activation/transduction
    • Engineering
    • Tandem CAR
    • iCAR
    • Ab-coupled TCR (ATCR)
    • Modulation of CAR potency
    • Adoptive T Cell Major Challenges in Solid Tumors
    • Tumor/Ag heterogeneity
    • Tumor associated Antigen
    • Microenvironment
    • Delivery/homing
    • Combinations
    • Persistence of CAR-T
    • In vivo proliferation and activation of CAR-T
    • Accessibility of tumor cells
    • Cell procurement
    • Autologous
    • Ex Vivo & In Vivo Strategy
    • Ex Vivo & In Vivo Strategy
Français English